Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in:

07-12-2024 | Leg Ulcer | Research

Livedoid vasculopathy in hemoglobinopathy-associated chronic leg ulcers

Authors: Harish Eswaran, Samuel Wilson, Jane Little, Stephan Moll

Published in: Annals of Hematology | Issue 12/2024

Login to get access

Abstract

Chronic leg ulceration is a debilitating manifestation of hemoglobinopathies, and best management is uncertain. Livedoid vasculopathy (LV) is a cutaneous non-inflammatory thrombotic vasculopathy treated with anticoagulation that has been identified in hemoglobinopathy-associated chronic leg ulceration. However, most patients with hemoglobinopathy-associated ulcers do not undergo workup for secondary causes, and the prevalence and relevance of LV is unclear. Outcomes of secondary workup were examined retrospectively in this study. 108 patients with hemoglobinopathy-associated chronic leg ulcers were identified. 15% of patients underwent skin biopsy, and 97% of biopsies showed non-specific findings. Two patients had LV and neither responded to anticoagulants. Livedoid vasculopathy is a rare cause of ulceration in hemoglobin gene disorders and the benefit of anticoagulation in these cases is unclear.
Literature
1.
Spira JAO, Borges EL, Júnior JFP, Monteiro DS, Kitagawa KY (2020) Estimated costs in treating sickle cell disease leg ulcer. Rev Esc Enferm USP 54:e03582CrossRefPubMed
2.
Minniti CP, Delaney KM, Gorbach AM, Xu D, Lee CC, Malik N et al (2014) Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia. Am J Hematol 89(1):1–6CrossRefPubMed
3.
Minniti CP, Kato GJ (2016) Critical reviews: how we treat sickle cell patients with leg ulcers. Am J Hematol 91(1):22–30CrossRefPubMed
4.
Micieli R, Alavi A (2018) Treatment for Livedoid Vasculopathy: a systematic review. JAMA Dermatol 154(2):193–202CrossRefPubMed
5.
Alavi A, Hafner J, Dutz JP, Mayer D, Sibbald RG, Criado PR et al (2013) Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach. J Am Acad Dermatol 69(6):1033–42e1CrossRefPubMed
6.
Reagin H, Marks E, Weis S, Susa J (2018) Livedoid Vasculopathy presenting in a patient with Sickle Cell Disease. Am J Dermatopathol 40(9):682–685CrossRefPubMed
7.
Stevens DM, Shupack JL, Javid J, Silber R (1977) Ulcers of the leg in Thalassemia. Arch Dermatol 113(11):1558–1560CrossRefPubMed
8.
Maus EA (2012) The importance of challenging your diagnosis even in straightforward cases. BMJ Case Rep.;10.1136/bcr-2012-006337:1–3
9.
Mekkes JR, Loots MA, Van Der Wal AC, Bos JD (2003) Causes, investigation and treatment of leg ulceration. Br J Dermatol 148(3):388–401CrossRefPubMed
10.
Eswaran H, Googe P, Vedak P, Marston WA, Moll S (2022) Livedoid vasculopathy: a review with focus on terminology and pathogenesis. Vasc Med 27(6):593–603CrossRefPubMedPubMedCentral
11.
Faes C, Sparkenbaugh EM, Pawlinski R (2018) Hypercoagulable state in sickle cell disease. Clin Hemorheol Microcirc 68(2–3):301–318CrossRefPubMed
12.
Taher AT, Cappellini MD, Musallam KM (2019) Development of a thalassemia-related thrombosis risk scoring system. Am J Hematol 94(8):E207–E9CrossRefPubMed
13.
Naik RP, Streiff MB, Lanzkron S (2013) Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis 35(3):352–358CrossRefPubMedPubMedCentral
14.
Cacciola E, Giustolisi R, Musso R, Longo A (1989) Antithrombin III concentrate for treatment of chronic leg ulcers in sickle cell-beta thalassemia: a pilot study. Ann Intern Med 111(6):534–536CrossRefPubMed
15.
Seguí M, Llamas-Velasco M (2022) A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy. Front Med (Lausanne) 9:993515CrossRefPubMed
16.
Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider SW, Gerss J et al (2016) Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol 3(2):e72–e79CrossRefPubMed
17.
Bilgic A, Ozcobanoglu S, Bozca BC, Alpsoy E (2021) Livedoid vasculopathy: a multidisciplinary clinical approach to diagnosis and management. Int J Womens Dermatol 7(5Part A):588–599CrossRefPubMedPubMedCentral
18.
Sirieix ME, Debure C, Baudot N, Dubertret L, Roux ME, Morel P et al (1999) Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol 135(7):818–820CrossRefPubMed
19.
Shanmugam VK, Angra D, Rahimi H, McNish S (2017) Vasculitic and autoimmune wounds. J Vasc Surg Venous Lymphat Disord 5(2):280–292CrossRefPubMed
20.
Tolu SS, Crouch A, Choi J, Gao Q, Reyes-Gil M, Ogu UO et al (2022) Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease. Ann Hematol 101(3):541–548CrossRefPubMed
Metadata
Title
Livedoid vasculopathy in hemoglobinopathy-associated chronic leg ulcers
Authors
Harish Eswaran
Samuel Wilson
Jane Little
Stephan Moll
Publication date
07-12-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 12/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-06112-0

Other articles of this Issue 12/2024

Non-linear relationship between soluble interleukin-2 receptor and prognosis of diffuse large B-cell lymphoma

Association of albumin to urea nitrogen ratio with 30-day mortality in adult hemophagocytic lymphohistiocytosis: a retrospective cohort study

A girl with a novel nonsense mutation in Chediak-Higashi syndrome was relieved successfully by treatment with HCST and UCBT: a case report

Identification of a novel cryptic variant chromosomal rearrangement involving 9q34, 22q11.2, and 5q22 resulting in ins(9;22) and t(5;22) in chronic myeloid leukemia: a case report

mTOR inhibitors potentially preserve fertility in female patients with haematopoietic malignancies: a narrative review

Prognostic significance of GATA2 in patients with MDS/AML: a systematic review and meta-analysis

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video
Image Credits